Company intelligence / Profile preview

Ionis Pharmaceuticals

Carlsbad, California, United Statesen.wikipedia.org ↗

Ownership: Public · IONS
Employees: ~1069
Development stage: Commercial

Overview

Ionis has six marketed medicines including Spinraza (nusinersen) for spinal muscular atrophy, Tegsedi (inotersen) for polyneuropathy, Waylivra (volanesorsen) for familial chylomicronemia syndrome, Qalsody (tofersen) for SOD1-ALS, and Wainua (eplontersen) for ATTRv-PN. The company has a rich pipeline of investigational medicines in various stages of development.

Therapeutic areas: CardiovascularMetabolic DisordersImmunologyHematologyNeurology
Modalities: RNA-targeted therapeuticsantisense oligonucleotides
Industry: Biotech

Drug pipeline

104 assets

zilganersen

Approved

103 more assets in the full pipeline.

Request access →

Partnerships

BiogenGSKOtsukaRoche

Financials

Market cap: $9.2B
Total revenue: $267.9M
Enterprise value: $9.6B

Beyond the preview

Go deeper on Ionis Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ionis Pharmaceuticals.

Explore the full profile